form8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

January 11, 2011
(Date of earliest event reported)

LABORATORY CORPORATION OF
AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)

Delaware
  
1-11353
  
13-3757370
(State or other jurisdiction of Incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)

358 South Main Street,
        
Burlington, North Carolina
  
27215
  
336-229-1127
(Address of principal executive offices)
  
(Zip Code)
  
(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01
Regulation FD Disclosure
 
Summary information of the Company in connection with the presentation at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 12, 2011.

 
 
 
SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant


 
By:
/s/ F. SAMUEL EBERTS III
   
F. Samuel Eberts III
   
Chief Legal Officer and Secretary


January 11, 2011
 
 
 
 
January 12, 2011
San Francisco, CA
 
29th Annual J.P. Morgan
Healthcare Conference
 
 
 
2
This slide presentation contains forward-looking
statements which are subject to change based
on various important factors, including without
limitation, competitive actions in the marketplace
and adverse actions of governmental and other
third-party payors.
Actual results could differ materially from those
suggested by these forward-looking statements.
Further information on potential factors that
could affect the Company’s financial results is
included in the Company’s Form 10-K for the
year ended December 31, 2009, and
subsequent SEC filings.
Forward Looking Statement
 
 
 
Introduction
3
Leading National
Lab Provider
• Fastest growing national lab
• $55 billion market
• Clinical, Anatomic and Genomic Testing
• Serving clients in all 50 states and Canada
• Foremost clinical trials testing business
 
 
 
Introduction
4
 
 
 
Valuable Service
• Small component of total cost
 influences large percentage
 of clinical decisions
• Screening, early detection,
 and monitoring reduce
 downstream costs
• Companion diagnostics
 improve drug efficacy and
 reduce adverse drug effects
 
Attractive Market
5
 
 
 
Attractive Market
6
Growth Drivers
• Aging population
• Industry consolidation
• Advances in genomics
• Pharmacogenomics /
 companion diagnostics
• Cost pressures
Source: CDC National Ambulatory Medical Care Survey and Company Estimates
 
 
 
Attractive Market
7
Opportunity to
Take Share
• Approximately 5,000
 independent labs
• Less efficient, higher cost
 competitors
Source: Washington G-2 Reports and company estimates
$55 Billion US Lab Market
55%
14%
9%
4%
19%
Hospital Affiliated
Quest
LabCorp
Physician Office
Other Independent
 
 
 
Attractive Market
Diversified Payor Mix
• No customer > 9% of revenue
• Limited government exposure
8
 
 
 
Attractive Market
Diversified Test Mix
With Genzyme Genetics
acquisition, esoteric testing
comprises 40% of revenue
9
 
 
 
Competitive Position
Scale and Scope
• National infrastructure
• Broad test offering
• Managed care contracts
• Economies of scale
10
Primary LabCorp Testing Locations*
Esoteric Lab Locations
(CET, CMBP, Dianon, Esoterix, Monogram Biosciences, NGI, OTS, US Labs, Viromed)
Patient Service Centers*
 
 
 
Competitive Position
11
Managed Care Relationships
• Exclusive national laboratory for UnitedHealthcare
• Sole national strategic partner for WellPoint
• Significant national plans recently renewed or
 extended on a multi-year basis, including
 WellPoint, Cigna and Humana
• Contracted with numerous local and
 regional anchor plans
 
 
 
Scientific
Leadership
• Introduction of new tests
• Acquisitions and licensing
• Collaborations with leading
 companies and academic
 institutions
Competitive Position
12
Partner
Clinical Area
ARCA biopharma
Companion Diagnostics (Cardiovascular Disease)
BG Medicine
Cardiovascular Disease
Celera Diagnostics
Breast Cancer
Duke University
Joint Venture in biomarker development
Duke University
Lung Cancer
Exact Sciences
Colon Cancer
Intema Ltd.
Prenatal Testing
Johns Hopkins
Melanoma
MDxHealth
Companion Diagnostics (Oncology)
Medco Health Solutions
Companion Diagnostics (Research)
Merck
Companion Diagnostics (Infectious Disease)
On-Q-ity
Circulating tumor cells
University of Minnesota
Lupus
Veridex
Prostate Cancer
Yale University
Ovarian Cancer (exclusive)
 
 
 
Competitive Position
13
Most Efficient and
Lowest Cost Provider
• Standardized lab and billing IT systems
• Automation of pre-analytics
• Supply chain optimization
• Sysmex fully automated hematology
 operations
• Gross margin improvement
• Bad debt reduction of 50bp in
 the first half of 2010
 
 
 
2010 Accomplishments
14
Our Results
• Profitable revenue growth
 • Empire contract
 • Esoteric growth
 • Acquisitions
• Improved IT and client connectivity
 • LabCorp Beacon
 • Enhanced experience
  for physicians and patients
• Continued scientific leadership
 • Clearstone collaboration
 • IL-28B
 • New Monogram assays
• Maintained price
 • Managed care stability
 • Strong YTD 2010 results
 
 
 
2011 Priorities
15
Our Focus
• Operating objectives
 • Genzyme integration
 • LabCorp Beacon rollout
 • Continue scientific leadership
• Financial objectives
 • Profitable revenue growth
 • Maintain price
 • Control costs
 
 
 
2011 Priorities - Genzyme Integration
16
Acquisition Rationale
• Creates the premier genetics and
 oncology business in the industry
• Builds on our strategy of leadership in
 personalized medicine
• Generates revenue opportunities
 • Selling LabCorp’s test menu to
  Genzyme accounts
 • Selling Genzyme’s test menu to
  LabCorp accounts
 • Genzyme customer access to
  LabCorp’s convenient PSC network
 • Expanded use of genetic counselors
• Creates cost synergies
 • Logistics
 • Specimen collection
 • G&A
 • Facility overlap
 
 
 
2011 Priorities - Genzyme Integration
Increasing Importance
of Genetics
• Preconception
• Pre - and post - natal
• Identification of disease carriers
• Identification of disease predisposition
• Diagnosis of genetically caused or
 influenced conditions (e.g., developmental delay)
• Disease prognosis and treatment
 (especially cancer)
17
 
 
 
2011 Priorities - Genzyme Integration
Increasing Importance
of Oncology
• More sophisticated methods of cancer
 testing complement traditional biopsies
• Value of diagnostics for disease prognosis,
 and monitoring of progression
 and recurrence
• Critical role of testing in therapy
 selection
18
 
 
 
2011 Priorities - Beacon Rollout
19
Intuitive Order Entry
•Streamlined Ordering
Provider, Diagnosis, Test and
Collection information are all displayed
in a single screen
•Requisition and Account Logic
Automatically generates requisitions
with appropriate account numbers
•Key Time-saving Features
 • Send to PSC
 • Standing orders
 • Electronic add-on testing
 • User-defined pick lists
 
 
 
2011 Priorities - Beacon Rollout
20
AccuDraw Integration
•Reduce Errors
•Reduce Training Time
•Proven Results
Success in LabCorp Patient Service
Centers will be extended to
customers
 
 
 
2011 Priorities - Beacon Rollout
21
Unified Results
•Centralizes Lab Connectivity
View lab reports from DIANON
Systems, Esoterix, LabCorp,
Litholink, USLabs, and CMBP
•Share Results
Email, fax, print and annotations
make it easy to share critical
information
•Visual Cues
Supports physician decision making,
enhances the timeliness of patient
care and facilitates follow-up with
abnormal results in red and unread
reports in bold
 
 
 
2011 Priorities - Beacon Rollout
22
Results on the Go
•Clear, Concise Reports
Physicians and staff can quickly
access results via iPhone® or
iPad™ including alerts for abnormal
or critical lab results
•Connect to Patients
Access patient demographics
directly from the results for phone or
email follow up
 
 
 
2011 Priorities - Beacon Rollout
23
Trends & Analytics
•One-Click Trending
Physicians and staff can quickly view
a single test or analyte for one
patient and the trended history for
that patient
•Sort and Filter Results
Providers can filter their entire
patient population on
demographics and test results to
identify trends and patients at risk
•View Lab History
 
 
 
2011 Priorities - Scientific Leadership
24
“K-RAS testing should be routinely conducted in
all colorectal cancer patients immediately after
diagnosis to ensure the best treatment strategies
for the individual Patient”
- Dr. Eric Van Cutsem, presenter at the June 2008 American
Society of Clinical Oncology meeting
FDA recommends genetic screening prior to
treatment with Abacavir
ROCKVILLE, Md -- July 24, 2008 -- The US Food and Drug Administration (FDA) has
issued an alert regarding serious, and sometimes fatal, hypersensitivity reactions (HSRs)
caused by abacavir (Ziagen) therapy in patients with a particular human leukocyte antigen
(HLA) allele, HLA-B* 5701.
Genetic tests for HLA-B*5701 are already available, and all patients should be screened for
the HLA-B*5701 allele before starting or restarting treatment with abacavir or abacavir-
containing medications.
“FDA has approved the expanded use of
Selzentry… to include adult patients with CCR5-
tropic HIV-1 virus who are starting treatment for
the first time.”
 - ViiV Healthcare Press Release, November 20th, 2009
Continue Scientific
Leadership
• Recent offerings in companion
 diagnostics and personalized medicine
 • IL-28B
 • K-RAS
 • HLA-B* 5701
 • BRAF Gene Mutation Detection
 • EGFR Mutation Analysis
 • CYP 450 2C19
 • Trofile® (CCR5 Tropism)
 • PhenoSense®, PhenoSense GT®
 • HERmark®
• Outcome Improvement Programs
 • CKD program
 • Litholink kidney stone program
• Clearstone collaboration
 • Global clinical trials capability
 • Presence in China
 
 
 
$3,085
$3,328
$3,591
$4,068
$4,513
$4,695
$2.45
$2.80
$3.30
$4.18
$4.60
$4.89
2004
2005
2006
2007
2008
2009
Revenue ($mil)
EPS
Excellent Performance
25
Revenue and
EPS Growth
• 5-year revenue CAGR of 9%
• 5-year EPS CAGR of 15%
(1) Excluding the $0.09 per diluted share impact in 2005 of restructuring and other special
charges, and a non-recurring investment loss; excluding the $0.06 per diluted share
impact in 2006 of restructuring and other special charges; excluding the $0.25 per
diluted share impact in 2007 of restructuring and other special charges; excluding the
(2) EPS, as presented, represents adjusted, non-GAAP financial measures. Diluted EPS,
as reported in the Company’s Annual Report were: $2.45 in 2004; $2.71 in 2005;
$3.24 in 2006; $3.93 in 2007; $4.16 in 2008; and $4.98 in 2009.
$0.44 per diluted share impact in 2008 of restructuring and other special charges; excluding
the ($0.09) per diluted share impact in 2009 of restructuring and other special charges.
Revenue and EPS Growth: 2004 - 2009 (1) (2)
 
 
 
Excellent Performance
26
Leading Returns
• Leading returns
• Leading EBIT margin
18.2%
20.5%
21.8%
27.6%
27.5%
25.8%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
2004
2005
2006
2007
2008
2009
LabCorp ROE 2004
-
2009
 
 
 
Excellent Performance
27
Cash Flow
• 5-year FCF CAGR of 11%
• Strategic acquisitions
• $2.0 B+ share repurchase
 over last three years
Note: $ in Millions
Note: Free Cash Flow is a non-GAAP metric
 
 
 
Excellent Performance
28
Free Cash Flow Per Share
• 5-year FCF Per Share CAGR of 18%
• FCF Yield ranged from approximately
 8% to 10% in 2010
Note: Free Cash Flow Per Share and Free Cash Flow Yield are non-GAAP metrics
 FCF Yield range noted above was calculated using trailing twelve month Free Cash Flow, weighted average diluted share counts and
 closing stock prices during 2010
 
 
 
Third Quarter and YTD 2010 Results
29
 
Three Months Ended Sep 30,
 
Nine Months Ended Sep 30,
 
 
2010
 
2009
 
+/(-)
 
2010
 
2009
 
+/(-)
 
Revenue (1)
$1,276.5
 
$1,185.1
 
7.7%
 
$3,708.5
 
$3,529.7
 
5.1%
 
Adjusted Operating Income
$250.1
 
$237.6
 
5.3%
 
$764.2
 
$733.0
 
4.3%
 
Adjusted Operating Income
Margin
19.6%
 
20.0%
 
-40
bp
20.6%
 
20.8%
 
-20
bp
Adjusted EPS (1)
$1.47
 
$1.22
 
20.5%
 
$2.76
 
$2.51
 
10.0%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operating Cash Flow
$176.2
 
$246.4
 
-28.5%
 
$624.4
 
$637.7
 
-2.1%
 
Less: Capital Expenditures
($34.3)
 
($22.7)
 
51.1%
 
($93.3)
 
($77.1)
 
21.0%
 
Free Cash Flow
$141.9
 
$223.7
 
-36.6%
 
$531.1
 
$560.6
 
-5.3%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) During the first quarter of 2010 inclement weather reduced revenue by an estimated $23 million and EPS by approximately eight cents
 
 
 
 
 
 
Key Points
• Critical position in health care delivery system
• Attractive market
• Strong competitive position - well positioned to gain share
• Leadership in personalized medicine
• Excellent cash flow
• Strong balance sheet
Conclusion
30
 
 
 
Reconciliation of Non-GAAP Financial Measures
31
Reconciliation of non-GAAP Financial Measures
(In millions, except per share data)
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended Sep 30,
 
Nine Months Ended Sep 30,
Adjusted Operating Income
 
2010
 
2009
 
2010
 
2009
 
Operating income
 
$235.3
 
$234.9
 
$740.0
 
$720.1
 
Restructuring and other special charges (1) (2)
 
$14.8
 
$2.7
 
$24.2
 
$12.9
 
Adjusted operating income
 
$250.1
 
$237.6
 
$764.2
 
$733.0
 
 
 
 
 
 
 
 
 
 
Adjusted EPS
 
 
 
 
 
 
 
 
 
Diluted earnings per common share
 
$1.34
 
$1.21
 
$4.05
 
$3.67
 
Impact of restructuring and other special charges (1) (2)
 
$0.13
 
$0.01
 
$0.18
 
$0.07
 
Adjusted EPS
 
$1.47
 
$1.22
 
$4.23
 
$3.74
 
 
 
 
 
 
 
 
 
 
1) During the third quarter of 2010, the Company recorded restructuring and other special charges of $21.8 million, consisting of $10.9 million in professional fees and expenses associated with recent acquisitions; $7.0 million in bridge financing fees associated
with the signing of an asset purchase agreement for Genzyme Genetics; and $3.9 million in severance related liabilities associated with workforce reduction initiatives. The after tax impact of these charges decreased net earnings for the three months ended
September 30, 2010, by $13.4 million and diluted earnings per share by $0.13 ($13.4 million divided by 104.1 million shares).
During the first quarter of 2010, the Company recorded net charges of $9.3 million relating to severance payments and the closing of redundant and underutilized facilities as well as the write-off of development costs incurred on systems abandoned during the
quarter.
 
The after tax impact of these combined charges decreased net earnings for the nine months ended September 30, 2010, by $19.1 million and diluted earnings per share by $0.18 ($19.1 million divided by 105.4 million shares).
2) During the third quarter of 2009, the Company recorded a charge of approximately $2.7 million representing fees and expenses associated with its acquisition of Monogram Biosciences. The after tax impact of this charge reduced net earnings for the three
months ended September 30, 2009, by $1.6 million and diluted earnings per share by $0.01 ($1.6 million divided by 108.8 million shares).
During the second quarter of 2009, the Company recorded net charges of approximately $10.2 million ($6.1 million after tax) related to actions directed at reducing the Company’s redundant and underutilized facilities along with the related work force.
 
The after tax impact of these combined charges reduced net earnings for the nine months ended September 30, 2009, by $7.7 million and diluted earnings per share by $0.07 for the nine months ended September 30, 2009 ($7.7 million divided by 109.1).
 
 
 
Supplemental Financial Information
32
Laboratory Corporation of America
Other Financial Information
FY 2009 and Q1 - Q3 2010
($ in millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q1 09
 
Q2 09
 
Q3 09
 
Q4 09
 
Q1 10
 
Q2 10
 
Q3 10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bad debt as a percentage of sales
 
5.30%
 
5.30%
 
5.30%
 
5.30%
 
5.05%
 
4.80%
 
4.80%
Days sales outstanding
 
52
 
50
 
48
 
44
 
46
 
45
 
44
A/R coverage (Allow. for Doubtful Accts. / A/R)
 
19.5%
 
20.6%
 
21.9%
 
23.2%
 
21.7%
 
20.7%
 
20.4%
 
 
 
©2010 LabCorp. All rights reserved. 8026-0210